In products 1992 in El Paso, TX a randomized, double-blind, placebo controlled study of subjects (n=130) for with allergic rhinitis in 1992-1993 was conducted. The average IgE allergies level of the placebo treated subjects remained essentially flat, while the average IgE level for active treated subjects was reduced significantly from baseline to Day 30.7 In 1993 in El Paso, TX, valid subjects (n=66) returned a second set of symptom diaries which they had completed for days 365 to 395 (the same period, one year after the first set of symptom products diaries). The active group had mean symptom scores showing for statistically allergies significant products decreases from 1992 to 1993. The placebo group had increased symptoms in 1993. (The for and allergies relevant pollen counts at the study site in 1993 were much higher than in 1992, leading to expectation of higher symptoms.)7

Genentech products and Novartis are developing an anti-IgE monoclonal for antibody for asthma and allergic rhinitis. allergies In December products 1999 they announced positive study results. This is evidence that reducing for IgE results in a reduction of symptoms associated with IgE-mediated allergic disease.13 For allergies people who find they cannot adequately avoid the allergens, products the symptoms often can be controlled with medications. Effective for medications that can be prescribed by allergies a physician include antihistamines, topical nasal products steroids, and cromolyn for sodium - any of which can be used alone or in combination. Many effective antihistamines and allergies decongestants also are available without a prescription. Click here for allergy medication online.